Newcells Biotech to develop a new skin metabolism model using iPSC derived skin cells - Newcells

Retinal platform

An in vitro, light responsive, retinal model for accurate predictions of in vivo outcomes you can have confidence in.

aProximateTM

Kidney platform

The most advanced near-physiological high throughput kidney proximal tubule cells (PTC) model to investigate drug transport modalities in vitro.

Lung epithelia model

Lung model

A model to investigate airway physiology, viral infection, drug safety and environmental impacts on lung airway epithelia.

Sinusoid iPSC-derived Liver model

Liver model

We are developing a model of liver sinusoid derived from human induced pluripotent stem cells (iPSC).

Published 26th April 2016 | News

Newcells Biotech to develop a new skin metabolism model using iPSC derived skin cells

Newcells Biotech has been successful in partnering with Newcastle University to receive funding in a £100K phase I NC3R CRACK IT project to develop a new skin metabolism model using iPSC derived skin cells.

Working with academics Prof Mark Birch-Machin and Dr Peter Hanson from the Institute of Cellular Medicine, Newcells is using its expertise in cellular reprogramming and differentiation of iPSCs to provide cells that will be used to construct a new skin model that will enable understanding of skin metabolism of topical drugs and xenobiotics. The project titled Metaboderm was one of only three in the UK that received funding under the scheme and the project is sponsored by GSK, Unilever, Stiefel and Dstl.

Share This:
Tweet Post Share